PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/455, 31/70 — A1

(11) International Publication Number: WO 99/53921

(43) International Publication Date: 28 October 1999 (28.10.99)

(21) International Application Number: PCT/IT99/00088

(22) International Filing Date: 14 April 1999 (14.04.99)

(30) Priority Data:
RM98A000238 17 April 1998 (17.04.98) IT

(71) Applicant *(for all designated States except US)*: SIGMA–TAU HEALTHSCIENCE S.P.A. [IT/IT]; Via Treviso, 4, I–00040 Pomezia (IT).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: CAVAZZA, Claudio [IT/IT]; Piazza Campitelli, 2, I–00186 Roma (IT).

(74) Agents: CAVATTONI, Fabio et al.; Cavattoni – Raimondi, Viale dei Parioli, 160, I–00197 Roma (IT).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: COMPOSITION COMPRISING L–CARNITINE OR AN ALKANOYL L–CARNITINE AND NADH AND/OR NADPH

(57) Abstract

A composition is disclosed which comprises L–carnitine or an alkanoyl L–carnitine or the pharmacologically acceptable salt thereof and NADH and/or NADPH, useful as a dietary supplement for individuals engaging in strenuous physical exercise or asthenic subjects and, as a medicament, for treating the chronic fatigue syndrome and Parkinson's disease.